Next Biomedical Co.,Ltd. (KOSDAQ:389650)

Revenue by Product

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Endoscopic Hemostatic Agent	8.26B
Endoscopic Hemostatic Agent Growth	93.38%
Vascular Embolic Microspheres	788.73M
Vascular Embolic Microspheres Growth	34.02%
Vascular Embolic Microspheres -F	489.21M
Vascular Embolic Microspheres -F Growth	3337.65%
Other	8.40M
Other Growth	-15.98%
Other	8.40M
Other Growth	-15.98%

Revenue by Geography

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Other	68.96M
Europe	4.40B
United States	4.39B
South Korea	676.12M
South Korea Growth	-86.15%
Other	68.96M